#BEGIN_DRUGCARD DB01565

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
509-60-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C17H21NO3

# Chemical_IUPAC_Name:
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-triene-10,14-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2007-07-31 07:10:32 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Analgesics, Opioid
Narcotics

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Illicit
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Dihydromorphine

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1

# InChI_Key:
InChIKey=IJVCSMSMFSCRME-KBQPJGBKSA-N

# Indication:
Dihydromorphine is an opioid analgesic used for moderate to severe pain relief.

# KEGG_Compound_ID:
C11782

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1565

# Mechanism_Of_Action:
Not Available

# Melting_Point:
157 dec Â°C

# Molecular_Weight_Avg:
287.3535

# Molecular_Weight_Mono:
287.152143543

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.26

# Predicted_LogS:
-2.2

# Predicted_Water_Solubility:
1.82e+00 g/l

# Primary_Accession_No:
DB01565

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5359421

# PubChem_Substance_ID:
46506587

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:17 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Dihydromorphine

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15178355	Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30.
16777416	Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
19474215	Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. Epub 2009 May 27.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
OPRM1

# Drug_Target_1_GenBank_ID_Gene:
L25119

# Drug_Target_1_GenBank_ID_Protein:
452073

# Drug_Target_1_GeneCard_ID:
OPRM1

# Drug_Target_1_Gene_Name:
OPRM1

# Drug_Target_1_Gene_Sequence:
>1203 bp
ATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA
AGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC
CTGTCCGACCCATGCGGTCCGAACCGCACCAACCTGGGCGGGAGAGACAGCCTGTGCCCT
CCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG
TGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG
ATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC
AGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC
CTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC
TGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC
CGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT
GGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA
CTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTCGTGAAGATCTGTGTTTTCATC
TTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC
CTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC
ACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT
TACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG
CACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT
CTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT
GAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT
ACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC
TAA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10393893	Uhl GR, Sora I, Wang Z: The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7752-5.
7488213	Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L, Chuang RY: Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun. 1995 Nov 22;216(3):922-30.
7891175	Mestek A, Hurley JH, Bye LS, Campbell AD, Chen Y, Tian M, Liu J, Schulman H, Yu L: The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci. 1995 Mar;15(3 Pt 2):2396-406.
7905839	Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR: Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 1994 Jan 31;338(2):217-22.
7957926	Bare LA, Mansson E, Yang D: Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 1994 Nov 7;354(2):213-6.
9399694	Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D: Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry. 1997 Oct-Nov;2(6):490-4.
9689128	Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13.

# Drug_Target_1_HGNC_ID:
HGNC:8156

# Drug_Target_1_HPRD_ID:
02484

# Drug_Target_1_ID:
847

# Drug_Target_1_Locus:
6q24-q25

# Drug_Target_1_Molecular_Weight:
44780

# Drug_Target_1_Name:
Mu-type opioid receptor

# Drug_Target_1_Number_of_Residues:
400

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Alfentanil Pathway	SMP00413
Carfentanil Pathway	SMP00414
Codeine Pathway	SMP00405
Fentanyl Pathway	SMP00415
Heroin Pathway	SMP00407
Hydrocodone Pathway	SMP00411
Hydromorphone Pathway	SMP00410
Methadone Pathway	SMP00408
Morphine Pathway	SMP00406
Oxycodone Pathway	SMP00409
Oxymorphone Pathway	SMP00412
Remifentanil Pathway	SMP00416
Sufentanil Pathway	SMP00417

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Mu-type opioid receptor
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Receptor for beta-endorphin

# Drug_Target_1_SwissProt_ID:
P35372

# Drug_Target_1_SwissProt_Name:
OPRM_HUMAN

# Drug_Target_1_Synonyms:
MOR-1

# Drug_Target_1_Theoretical_pI:
8.29

# Drug_Target_1_Transmembrane_Regions:
67-96
106-123
146-165
196-211
237-259
283-305
314-330

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15178355	Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30.
16777416	Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
19474215	Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. Epub 2009 May 27.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
OPRD1

# Drug_Target_2_GenBank_ID_Gene:
U07882

# Drug_Target_2_GenBank_ID_Protein:
27545517

# Drug_Target_2_GeneCard_ID:
OPRD1

# Drug_Target_2_Gene_Name:
OPRD1

# Drug_Target_2_Gene_Sequence:
>1119 bp
ATGGAACCGGCCCCCTCCGCCGGCGCCGAGCTGCAGCCCCCGCTCTTCGCCAACGCCTCG
GACGCCTACCCTAGCGCCTTCCCCAGCGCTGGCGCCAATGCGTCGGGGCCGCCAGGCGCG
CGGAGCGCCTCGTCCCTCGCCCTGGCAATCGCCATCACCGCGCTCTACTCGGCCGTGTGC
GCCGTGGGGCTGCTGGGCAACGTGCTTGTCATGTTCGGCATCGTCCGGTACACTAAGATG
AAGACGGCCACCAACATCTACATCTTCAACCTGGCCTTAGCCGATGCGCTGGCCACCAGC
ACGCTGCCTTTCCAGAGTGCCAAGTACCTGATGGAGACGTGGCCCTTCGGCGAGCTGCTC
TGCAAGGCTGTGCTCTCCATCGACTACTACAATATGTTCACCAGCATCTTCACGCTCACC
ATGATGAGTGTTGACCGCTACATCGCTGTCTGCCACCCTGTCAAGGCCCTGGACTTCCGC
ACGCCTGCCAAGGCCAAGCTGATCAACATCTGTATCTGGGTCCTGGCCTCAGGCGTTGGC
GTGCCCATCATGGTCATGGCTGTGACCCGTCCCCGGGACGGGGCAGTGGTGTGCATGCTC
CAGTTCCCCAGCCCCAGCTGGTACTGGGACACGGTGACCAAGATCTGCGTGTTCCTCTTC
GCCTTCGTGGTGCCCATCCTCATCATCACCGTGTGCTATGGCCTCATGCTGCTGCGCCTG
CGCAGTGTGCGCCTGCTGTCGGGCTCCAAGGAGAAGGACCGCAGCCTGCGGCGCATCACG
CGCATGGTGCTGGTGGTTGTGGGCGCCTTCGTGGTGTGTTGGGCGCCCATCCACATCTTC
GTCATCGTCTGGACGCTGGTGGACATCGACCGGCGCGACCCGCTGGTGGTGGCTGCGCTG
CACCTGTGCATCGCGCTGGGCTACGCCAATAGCAGCCTCAACCCCGTGCTCTACGCTTTC
CTCGACGAGAACTTCAAGCGCTGCTTCCGCCAGCTCTGCCGCAAGCCCTGCGGCCGCCCA
GACCCCAGCAGCTTCAGCCGCGCCCGCGAAGCCACGGCCCGCGAGCGTGTCACCGCCTGC
ACCCCGTCCGATGGTCCCGGCGGTGGCGCTGCCGCCTGA

# Drug_Target_2_General_Function:
Involved in delta-opioid receptor activity

# Drug_Target_2_General_References:
10982041	Gelernter J, Kranzler HR: Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Hum Genet. 2000 Jul;107(1):86-8.
7808419	Simonin F, Befort K, Gaveriaux-Ruff C, Matthes H, Nappey V, Lannes B, Micheletti G, Kieffer B: The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol Pharmacol. 1994 Dec;46(6):1015-21.
8201839	Knapp RJ, Malatynska E, Fang L, Li X, Babin E, Nguyen M, Santoro G, Varga EV, Hruby VJ, Roeske WR, et al.: Identification of a human delta opioid receptor: cloning and expression. Life Sci. 1994;54(25):PL463-9.

# Drug_Target_2_HGNC_ID:
HGNC:8153

# Drug_Target_2_HPRD_ID:
01308

# Drug_Target_2_ID:
467

# Drug_Target_2_Locus:
1p36.1-p34.3

# Drug_Target_2_Molecular_Weight:
40413

# Drug_Target_2_Name:
Delta-type opioid receptor

# Drug_Target_2_Number_of_Residues:
372

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Delta-type opioid receptor
MEPAPSAGAELQPPLFANASDAYPSAFPSAGANASGPPGARSASSLALAIAITALYSAVC
AVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELL
CKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVG
VPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRL
RSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAAL
HLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTAC
TPSDGPGGGAAA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Highly stereoselective. receptor for enkephalins

# Drug_Target_2_SwissProt_ID:
P41143

# Drug_Target_2_SwissProt_Name:
OPRD_HUMAN

# Drug_Target_2_Synonyms:
DOR-1

# Drug_Target_2_Theoretical_pI:
9.17

# Drug_Target_2_Transmembrane_Regions:
46-75
85-102
125-144
175-190
216-238
262-284
294-310

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
15178355	Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30.
16777416	Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
19474215	Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. Epub 2009 May 27.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
OPRK1

# Drug_Target_3_GenBank_ID_Gene:
U11053

# Drug_Target_3_GenBank_ID_Protein:
532060

# Drug_Target_3_GeneCard_ID:
OPRK1

# Drug_Target_3_Gene_Name:
OPRK1

# Drug_Target_3_Gene_Sequence:
>1143 bp
ATGGAATCCCCGATTCAGATCTTCCGCGGGGAGCCTGGCCCTACCTGCGCCCCGAGCGCC
TGCCTGCCCCCCAACAGCAGCGCCTGGTTTCCCGGCTGGGCCGAGCCCGACAGCAACGGC
AGCGCCGGCTCGGAGGACGCGCAGCTGGAGCCCGCGCACATCTCCCCGGCCATCCCGGTC
ATCATCACGGCGGTCTACTCCGTAGTGTTCGTCGTGGGCTTGGTGGGCAACTCGCTGGTC
ATGTTCGTGATCATCCGATACACAAAGATGAAGACAGCAACCAACATTTACATATTTAAC
CTGGCTTTGGCAGATGCTTTAGTTACTACAACCATGCCCTTTCAGAGTACGGTCTACTTG
ATGAATTCCTGGCCTTTTGGGGATGTGCTGTGCAAGATAGTAATTTCCATTGATTACTAC
AACATGTTCACCAGCATCTTCACCTTGACCATGATGAGCGTGGACCGCTACATTGCCGTG
TGCCACCCCGTGAAGGCTTTGGACTTCCGCACACCCTTGAAGGCAAAGATCATCAATATC
TGCATCTGGCTGCTGTCGTCATCTGTTGGCATCTCTGCAATAGTCCTTGGAGGCACCAAA
GTCAGGGAAGACGTCGATGTCATTGAGTGCTCCTTGCAGTTCCCAGATGATGACTACTCC
TGGTGGGACCTCTTCATGAAGATCTGCGTCTTCATCTTTGCCTTCGTGATCCCTGTCCTC
ATCATCATCGTCTGCTACACCCTGATGATCCTGCGTCTCAAGAGCGTCCGGCTCCTTTCT
GGCTCCCGAGAGAAAGATCGCAACCTGCGTAGGATCACCAGACTGGTCCTGGTGGTGGTG
GCGGTTTTCGTCGTCTGCTGGACTCCCATTCACATATTCATCCTGGTGGAGGCTCTGGGG
AGCACCTCCCACAGCACAGCTGCTCTCTCCAGCTATTACTTCTGCATCGCCTTAGGCTAT
ACCAACAGTAGCCTGAATCCCATTCTCTACGCCTTTCTTGATGAAAACTTCAAGCGGTGT
TTCCGGGACTTCTGCTTTCCACTGAAGATGAGGATGGAGCGGCAGAGCACTAGCAGAGTC
CGAAATACAGTTCAGGATCCTGCTTACCTGAGGGACATCGATGGGATGAATAAACCAGTA
TGA

# Drug_Target_3_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_3_General_References:
12004055	Li JG, Chen C, Liu-Chen LY: Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human kappa opioid receptor by enhancing its recycling rate. J Biol Chem. 2002 Jul 26;277(30):27545-52. Epub 2002 May 9.
7624359	Simonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattei MG, Charron G, Bloch B, Kieffer B: kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7006-10.
7869844	Zhu J, Chen C, Xue JC, Kunapuli S, DeRiel JK, Liu-Chen LY: Cloning of a human kappa opioid receptor from the brain. Life Sci. 1995;56(9):PL201-7.
7929306	Wang JB, Johnson PS, Wu JM, Wang WF, Uhl GR: Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras. J Biol Chem. 1994 Oct 21;269(42):25966-9.
8060324	Mansson E, Bare L, Yang D: Isolation of a human kappa opioid receptor cDNA from placenta. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1431-7.

# Drug_Target_3_HGNC_ID:
HGNC:8154

# Drug_Target_3_HPRD_ID:
01309

# Drug_Target_3_ID:
696

# Drug_Target_3_Locus:
8q11.2

# Drug_Target_3_Molecular_Weight:
42646

# Drug_Target_3_Name:
Kappa-type opioid receptor

# Drug_Target_3_Number_of_Residues:
380

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Kappa-type opioid receptor
MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPV
IITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYL
MNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINI
CIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVL
IIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALG
STSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRV
RNTVQDPAYLRDIDGMNKPV

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Receptor for dynorphins. May play a role in arousal and regulation of autonomic and neuroendocrine functions

# Drug_Target_3_SwissProt_ID:
P41145

# Drug_Target_3_SwissProt_Name:
OPRK_HUMAN

# Drug_Target_3_Synonyms:
KOR-1

# Drug_Target_3_Theoretical_pI:
7.79

# Drug_Target_3_Transmembrane_Regions:
59-85
96-117
133-154
174-196
223-247
276-299
312-333

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
1654566	Liebmann C, Schnittler M, Hartrodt B, Born I, Neubert K: Structure-activity studies of novel casomorphin analogues: binding profiles towards mu 1-, mu 2- and delta -opioid receptors. Pharmazie. 1991 May;46(5):345-8.
2828423	Maneckjee R, Archer S, Zukin RS: Characterization of a polyclonal antibody to the mu opioid receptor. J Neuroimmunol. 1988 Feb;17(3):199-208.
2835832	Ishizuka Y, Oka T: Relation of diltiazem binding sites to opioid receptor subtypes in the guinea-pig brain. Tokai J Exp Clin Med. 1987 Mar;12(1):11-7.
2855368	Koman A, Kolb VM, Terenius L: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. Pharm Res. 1987 Apr;4(2):147-9.
2985086	Ho CL, Hammonds RG Jr, Li CH: Opiate receptor binding profile in the rabbit cerebellum and brain membranes. Biochem Pharmacol. 1985 Apr 1;34(7):925-31.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
TRIM13

# Drug_Target_4_GenBank_ID_Gene:
AJ224819

# Drug_Target_4_GenBank_ID_Protein:
3133092

# Drug_Target_4_GeneCard_ID:
TRIM13

# Drug_Target_4_Gene_Name:
TRIM13

# Drug_Target_4_Gene_Sequence:
>1224 bp
ATGGAGCTGCTTGAAGAAGATCTCACATGCCCTATTTGTTGTAGTCTGTTTGATGATCCA
CGGGTTTTGCCTTGCTCCCACAACTTCTGCAAAAAATGCTTAGAAGGTATCTTAGAAGGG
AGTGTGCGGAATTCCTTGTGGAGACCAGCTCCATTCAAGTGTCCTACATGCCGTAAGGAA
ACTTCAGCTACTGGAATTAATAGCCTGCAGGTTAATTACTCCCTGAAGGGTATTGTGGAA
AAGTATAACAAGATCAAGATCTCTCCCAAAATGCCAGTATGCAAAGGACACTTGGGGCAG
CCTCTCAACATTTTCTGCCTGACTGATATGCAGCTGATTTGTGGGATCTGTGCTACTCGT
GGGGAGCACACCAAACATGTCTTCTGTTCTATTGAAGATGCCTATGCTCAGGAAAGGGAT
GCCTTTGAGTCCCTCTTCCAGAGCTTTGAGACCTGGCGTCGGGGAGATGCTCTTTCTCGC
TTGGATACCTTGGAAACTAGTAAGAGGAAATCCCTACAGTTACTGACTAAAGATTCAGAT
AAAGTGAAGGAATTTTTTGAGAAGTTACAACACACACTGGATCAAAAGAAGAATGAAATT
CTGTCTGACTTTGAGACCATGAAACTTGCTGTTATGCAAGCATATGACCCAGAGATCAAC
AAACTCAACACCATCTTGCAGGAGCAACGGATGGCCTTTAACATTGCTGAGGCTTTCAAA
GATGTGTCAGAACCCATTGTATTTCTGCAACAGATGCAGGAGTTTAGAGAGAAAATCAAA
GTAATCAAGGAAACTCCTTTACCTCCCTCTAATTTGCCTGCAAGCCCTTTAATGAAGAAC
TTTGATACCAGTCAGTGGGAAGACATAAAACTAGTCGATGTGGATAAACTTTCTTTGCCT
CAAGACACTGGCACATTCATTAGCAAGATTCCCTGGAGCTTTTATAAGTTATTTTTGCTA
ATCCTTCTGCTTGGCCTTGTCATTGTCTTTGGTCCTACCATGTTCCTAGAATGGTCATTA
TTTGATGACCTGGCAACTTGGAAAGGCTGTCTTTCAAACTTCACTTCCTATCTGACTAAA
ACAGCCGATTTCATAGAACAATCAGTTTTTTACTGGGAACAGGTGACAGATGGGTTTTTC
ATTTTCAATGAAAGATTCAAGAATTTTACTTTGGTGGTACTGAACAATGTGGCAGAATTT
GTGTGCAAATATAAACTATTATAA

# Drug_Target_4_General_Function:
Involved in zinc ion binding

# Drug_Target_4_General_References:
11161783	Kapanadze B, Makeeva N, Corcoran M, Jareborg N, Hammarsund M, Baranova A, Zabarovsky E, Vorontsova O, Merup M, Gahrton G, Jansson M, Yankovsky N, Einhorn S, Oscier D, Grander D, Sangfelt O: Comparative sequence analysis of a region on human chromosome 13q14, frequently deleted in B-cell chronic lymphocytic leukemia, and its homologous region on mouse chromosome 14. Genomics. 2000 Dec 15;70(3):327-34.
11264177	Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV, Gaidano G, Inghirami G, Zhang P, Fischer S, Kalachikov SM, Russo J, Edelman I, Efstratiadis A, Dalla-Favera R: Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood. 2001 Apr 1;97(7):2098-104.
11331580	Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A: The tripartite motif family identifies cell compartments. EMBO J. 2001 May 1;20(9):2140-51.
9599022	Kapanadze B, Kashuba V, Baranova A, Rasool O, van Everdink W, Liu Y, Syomov A, Corcoran M, Poltaraus A, Brodyansky V, Syomova N, Kazakov A, Ibbotson R, van den Berg A, Gizatullin R, Fedorova L, Sulimova G, Zelenin A, Deaven L, Lehrach H, Grander D, Buys C, Oscier D, Zabarovsky ER, Einhorn S, Yankovsky N: A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5. FEBS Lett. 1998 Apr 17;426(2):266-70.

# Drug_Target_4_HGNC_ID:
HGNC:9976

# Drug_Target_4_HPRD_ID:
10414

# Drug_Target_4_ID:
1716

# Drug_Target_4_Locus:
13q14

# Drug_Target_4_Molecular_Weight:
46988

# Drug_Target_4_Name:
Tripartite motif-containing protein 13

# Drug_Target_4_Number_of_Residues:
407

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00097	zf-C3HC4
PF00643	zf-B_box

# Drug_Target_4_Protein_Sequence:
>Tripartite motif-containing protein 13
MELLEEDLTCPICCSLFDDPRVLPCSHNFCKKCLEGILEGSVRNSLWRPAPFKCPTCRKE
TSATGINSLQVNYSLKGIVEKYNKIKISPKMPVCKGHLGQPLNIFCLTDMQLICGICATR
GEHTKHVFCSIEDAYAQERDAFESLFQSFETWRRGDALSRLDTLETSKRKSLQLLTKDSD
KVKEFFEKLQHTLDQKKNEILSDFETMKLAVMQAYDPEINKLNTILQEQRMAFNIAEAFK
DVSEPIVFLQQMQEFREKIKVIKETPLPPSNLPASPLMKNFDTSQWEDIKLVDVDKLSLP
QDTGTFISKIPWSFYKLFLLILLLGLVIVFGPTMFLEWSLFDDLATWKGCLSNFSSYLTK
TADFIEQSVFYWEQVTDGFFIFNERFKNFTLVVLNNVAEFVCKYKLL

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
May act as a tumor suppressor

# Drug_Target_4_SwissProt_ID:
O60858

# Drug_Target_4_SwissProt_Name:
TRI13_HUMAN

# Drug_Target_4_Synonyms:
B- cell chronic lymphocytic leukemia tumor suppressor Leu5
Leukemia-associated protein 5
Putative tumor suppressor RFP2
RING finger protein 77
Ret finger protein 2

# Drug_Target_4_Theoretical_pI:
5.80

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
29252	Somoza E: Influence of neuroleptics on the binding of met-enkephalin, morphine and dihydromorphine to synaptosome-enriched fractions of rat brain. Neuropharmacology. 1978 Aug;17(8):577-81.
6292632	Johnson N, Houghten R, Pasternak GW: Binding of 3H-beta-endorphin in rat brain. Life Sci. 1982 Sep 20-27;31(12-13):1381-4.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
POMC

# Drug_Target_5_GenBank_ID_Gene:
M38297

# Drug_Target_5_GenBank_ID_Protein:
190188

# Drug_Target_5_GeneCard_ID:
POMC

# Drug_Target_5_Gene_Name:
POMC

# Drug_Target_5_Gene_Sequence:
>789 bp
TGCAGCCGCTCGGGGGCCCTGTTGCTGGCCTTGCTGCTTCAGGCCTCCATGGAAGTGCGT
GGCTGGTGCCTGGAGAGCAGCCAGTGTCAGGACCTCACCACGGAAAGCAACCTGCTGGAG
TGCATCCGGGCCTGCAAGCCCGACCTCTCGGCCGAGACTCCCATGTTCCCGGGAAATGGC
GACGAGCAGCCTCTGACCGAGAACCCCCGGAAGTACGTCATGGGCCACTTCCGCTGGGAC
CGATTCGGCCGCCGCAACAGCAGCAGCAGCGGCAGCAGCGGCGCAGGGCAGAAGCGCGAG
GACGTCTCAGCGGGCGAAGACTGCGGCCCGCTGCCTGAGGGCGGCCCCGAGCCCCGCAGC
GATGGTGCCAAGCCGGGCCCGCGCGAGGGCAAGCGCTCCTACTCCATGGAGCACTTCCGC
TGGGGCAAGCCGGTGGGCAAGAAGCGGCGCCCAGTGAAGGTGTACCCTAACGGCGCCGAG
GACGAGTCGGCCGAGGCCTTCCCCCTGGAGTTCAAGAGGGAGCTGACTGGCCAGCGACTC
CGGGAGGGAGATGGCCCCGACGGCCCTGCCGATGACGGCGCAGGGGCCCAGGCCGACCTG
GAGCACAGCCTGCTGGTGGCGGCCGAGAAGAAGGACGAGGGCCCCTACAGGATGGAGCAC
TTCCGCTGGGGCAGCCCGCCCAAGGACAAGCGCTACGGCGGTTTCATGACCTCCGAGAAG
AGCCAGACGCCCCTGGTGACGCTGTTCAAAAACGCCATCATCAAGAACGCCTACAAGAAG
GGCGAGTGA

# Drug_Target_5_General_Function:
Involved in hormone activity

# Drug_Target_5_General_References:
10193875	Echwald SM, Sorensen TI, Andersen T, Tybjaerg-Hansen A, Clausen JO, Pedersen O: Mutational analysis of the proopiomelanocortin gene in Caucasians with early onset obesity. Int J Obes Relat Metab Disord. 1999 Mar;23(3):293-8.
11244459	Miraglia del Giudice E, Cirillo G, Santoro N, D'Urso L, Carbone MT, Di Toro R, Perrone L: Molecular screening of the proopiomelanocortin (POMC ) gene in Italian obese children: report of three new mutations. Int J Obes Relat Metab Disord. 2001 Jan;25(1):61-7.
1264228	Li CH, Chung D: Primary structure of human beta-lipotropin. Nature. 1976 Apr 15;260(5552):622-4.
195688	Dragon N, Seidah NG, Lis M, Routhier R, Chretien M: Primary structure and morphine-like activity of human beta-endorphin. Can J Biochem. 1977 Jun;55(6):666-70.
2424570	Bovenberg RA, Burbach JP, Wiegant VM, Veeneman GH, van Boom JH, Baas PD, Jansz HS, de Wied D: gamma-Endorphin and schizophrenia: amino acid composition of gamma-endorphin and nucleotide sequence of gamma-endorphin cDNA from pituitary glands of schizophrenic patients. Brain Res. 1986 Jun 18;376(1):29-37.
2839146	Fenger M, Johnsen AH: Alpha-amidated peptides derived from pro-opiomelanocortin in normal human pituitary. Biochem J. 1988 Mar 15;250(3):781-8.
3606677	Golovin SIa, Karginov VA, Bondar' AA, Beklemishev AB, Chekhranova MK: [Synthesis, cloning and primary structure of DNA complementary to mRNA for human pituitary pro-opiomelanocortin] Bioorg Khim. 1987 Apr;13(4):562-4.
4334191	Riniker B, Sieber P, Rittel W, Zuber H: Revised amino-acid sequences for porcine and human adrenocorticotrophic hormone. Nat New Biol. 1972 Jan 26;235(56):114-5.
4338630	Sieber P, Rittel W, Riniker B: [Synthesis of the human adrenal cortex hormone ( h ACTH) with a revised amino acid sequence] Helv Chim Acta. 1972;55(4):1243-66.
4347148	Yamashiro D, Li CH: Adrenocorticotropins. 44. Total synthesis of the human hormone by the solid-phase method. J Am Chem Soc. 1973 Feb 21;95(4):1310-5.
4352834	Bennett HP, Lowry PJ, McMartin C: Confirmation of the 1-20 amino acid sequence of human adrenocorticotrophin. Biochem J. 1973 May;133(1):11-3.
6254047	Chang AC, Cochet M, Cohen SN: Structural organization of human genomic DNA encoding the pro-opiomelanocortin peptide. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4890-4.
6267033	Seidah NG, Rochemont J, Hamelin J, Lis M, Chretien M: Primary structure of the major human pituitary pro-opiomelanocortin NH2-terminal glycopeptide. Evidence for an aldosterone-stimulating activity. J Biol Chem. 1981 Aug 10;256(15):7977-84.
6272808	Seidah NG, Rochemont J, Hamelin J, Benjannet S, Chretien M: The missing fragment of the pro-sequence of human pro-opiomelanocortin: sequence and evidence for C-terminal amidation. Biochem Biophys Res Commun. 1981 Sep 30;102(2):710-6.
6274691	Takahashi H, Teranishi Y, Nakanishi S, Numa S: Isolation and structural organization of the human corticotropin--beta-lipotropin precursor gene. FEBS Lett. 1981 Nov 30;135(1):97-102.
6299668	Whitfeld PL, Seeburg PH, Shine J: The human pro-opiomelanocortin gene: organization, sequence, and interspersion with repetitive DNA. DNA. 1982;1(2):133-43.
6314261	Takahashi H, Hakamata Y, Watanabe Y, Kikuno R, Miyata T, Numa S: Complete nucleotide sequence of the human corticotropin-beta-lipotropin precursor gene. Nucleic Acids Res. 1983 Oct 11;11(19):6847-58.
6945581	Seidah NG, Chretien M: Complete amino acid sequence of a human pituitary glycopeptide: an important maturation product of pro-opiomelanocortin. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4236-40.
7828531	Morris JC, Savva D, Lowry PJ: Reduced expression of a naturally deleted form of human proopiomelanocortin complementary deoxyribonucleic acid after transfection into Chinese hamster ovary cells. Endocrinology. 1995 Jan;136(1):195-201.
9768693	Hinney A, Becker I, Heibult O, Nottebom K, Schmidt A, Ziegler A, Mayer H, Siegfried W, Blum WF, Remschmidt H, Hebebrand J: Systematic mutation screening of the pro-opiomelanocortin gene: identification of several genetic variants including three different insertions, one nonsense and two missense point mutations in probands of different weight extremes. J Clin Endocrinol Metab. 1998 Oct;83(10):3737-41.

# Drug_Target_5_HGNC_ID:
HGNC:9201

# Drug_Target_5_HPRD_ID:
01462

# Drug_Target_5_ID:
1262

# Drug_Target_5_Locus:
2p23.3

# Drug_Target_5_Molecular_Weight:
29424

# Drug_Target_5_Name:
Corticotropin-lipotropin

# Drug_Target_5_Number_of_Residues:
267

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Codeine Pathway	SMP00405

# Drug_Target_5_Pfam_Domain_Function:
PF00976	ACTH_domain
PF08035	Op_neuropeptide
PF08384	NPP

# Drug_Target_5_Protein_Sequence:
>Corticotropin-lipotropin precursor
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQDLTTESNLLECIRACKPDLSAETPM
FPGNGDEQPLTENPRKYVMGHFRWDRFGRRNSSSSGSSGAGQKREDVSAGEDCGPLPEGG
PEPRSDGAKPGPREGKRSYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEFKREL
TGQRLREGDGPDGPADDGAGAQADLEHSLLVAAEKKDEGPYRMEHFRWGSPPKDKRYGGF
MTSEKSQTPLVTLFKNAIIKNAYKKGE

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
1-26

# Drug_Target_5_Specific_Function:
Beta-endorphin and Met-enkephalin are endogenous opiates

# Drug_Target_5_SwissProt_ID:
P01189

# Drug_Target_5_SwissProt_Name:
COLI_HUMAN

# Drug_Target_5_Synonyms:
Corticotropin-lipotropin precursor
POMC
Pro-opiomelanocortin

# Drug_Target_5_Theoretical_pI:
7.75

# Drug_Target_5_Transmembrane_Regions:
None

#END_DRUGCARD DB01565
